Bio-Techne Corp.

As of October 17, 2025, Bio-Techne Corp. is considered very expensive and overvalued with a P/E ratio of 37, significantly higher than its peers, and has underperformed with a year-to-date return of -14.12% compared to the S&P 500's 13.30% gain.

As of October 17, 2025, Bio-Techne Corp. is considered very expensive and overvalued due to its high P/E ratio of 37 and other valuation metrics, despite a recent short-term gain of 5.46% compared to the S&P 500's 1.70%.

As of October 3, 2025, Bio-Techne Corp. shows a neutral technical trend with mixed signals, indicating a shift from bearish to sideways, while significantly underperforming the S&P 500 with a year-to-date return of -12.61%.

As of October 3, 2025, Bio-Techne Corp. shows a neutral trend with mixed signals, having outperformed the S&P 500 in the short term but significantly underperformed over the longer term.

As of September 12, 2025, Bio-Techne Corp. is in a bearish trend with weak strength, indicated by bearish daily moving averages and monthly MACD, despite some mild bullishness in weekly indicators, and it has significantly underperformed the S&P 500 with a year-to-date return of -26.43%.

As of July 7, 2025, Bio-Techne Corp. is considered very expensive and overvalued, with a P/E ratio of 37 and an EV to EBITDA of 20.54, both significantly higher than its peers, alongside a disappointing year-to-date return of -26.43%.

As of June 9, 2025, the technical trend is mildly bearish, indicated by daily moving averages and weekly Bollinger Bands, despite some mildly bullish signals from the weekly MACD and KST, suggesting a cautious outlook amid significant underperformance compared to the S&P 500.

As of November 1, 2023, Bio-Techne Corp. is considered very expensive and overvalued with a P/E ratio of 37, a high PEG ratio of 12.84, and modest returns on capital and equity, while significantly underperforming the S&P 500 with a year-to-date return of -31.56%.

As of March 2022, the management team of Bio-Techne Corp. includes Independent Chairman Mr. Robert Baumgartner, President and CEO Mr. Charles Kummeth, and several Independent Directors: Ms. Julie Bushman, Mr. John Higgins, Dr. Joseph Keegan, Dr. Roeland Nusse, and Dr. Alpna Seth. This team provides governance and strategic direction for the company.

Bio-Techne Corporation develops and sells biotechnology reagents and instruments for research and clinical diagnostics, with recent net sales of $316 million and a market cap of approximately $7.76 billion. Key financial metrics include a P/E ratio of 37.00 and a dividend yield of 64.92%.

As of Jun 18, Bio-Techne Corp. has a market capitalization of $7.76 billion, with net sales of $1.21 billion and a net profit of $131.65 million reported over the latest four quarters.